You are here

China

Pharma fury as Trump’s team reneges on biologic patent rules in trade talks

Pharma fury as Trump’s team reneges on biologic patent rules in trade talks

Pharmaforum

Flag link:

AZ’s Imfinzi approved in early lung cancer in China

AZ’s Imfinzi approved in early lung cancer in China

Pharmaforum

non-small cell lung cancer

Flag link:

Merck Isn't Too Reliant on Keytruda Yet, and That's Good News for Investors

Merck Isn't Too Reliant on Keytruda Yet, and That's Good News for Investors

Motley Fool

Flag link:

Drugs firms make massive discounts to get reimbursement in China

Drugs firms make massive discounts to get reimbursement in China

Pharmaforum

Flag link:

Roche shows Tecentriq/Avastin combo helps liver cancer patients live longer

Roche shows Tecentriq/Avastin combo helps liver cancer patients live longer

Endpoints

clinical trials

Flag link:

Brii bags rights to tuberculosis drug to further antibiotic push

Brii bags rights to tuberculosis drug to further antibiotic push

Fierce Biotech

Brii Biosciences

AN2 Therapeutics

Flag link:

OxyContin maker thrives in China with abandoned U.S. tactics

OxyContin maker thrives in China with abandoned U.S. tactics

Stat

Flag link:

Novartis Cuts 150 Jobs As it Shifts Focus of Shanghai Facility to Drug Development

Novartis Cuts 150 Jobs As it Shifts Focus of Shanghai Facility to Drug Development

BioSpace

Flag link:

China's BeiGene gets FDA approval for drug to treat rare form of lymphoma

China's BeiGene gets FDA approval for drug to treat rare form of lymphoma

Yahoo/Reuters

mantle cell lymphoma

Flag link:

Ahead of FDA decision on BTK drug, Amgen-partnered BeiGene scores China OK for PD-1

Ahead of FDA decision on BTK drug, Amgen-partnered BeiGene scores China OK for PD-1

Endpoints

Flag link:

Top execs from AstraZeneca, Roche, Sanofi and GSK tout China investments at import expo

Top execs from AstraZeneca, Roche, Sanofi and GSK tout China investments at import expo

Fierce Pharma

Flag link:

AstraZeneca creates $1B Chinese fund, vows to double R&D team

AstraZeneca creates $1B Chinese fund, vows to double R&D team

Fierce Biotech

Flag link:

China's Alzheimer’s Drug Approval Raises Hopes and Skepticism

China's Alzheimer’s Drug Approval Raises Hopes and Skepticism

BioSpace

Alzheimer's disease

Shanghai Green Valley Pharmaceuticals

Flag link:

Chinese pharma claims first Alzheimer’s drug approval since 2003

Chinese pharma claims first Alzheimer’s drug approval since 2003

Pharmaforum

Alzheimer's disease

Shanghai Green Valley Pharmaceuticals

Flag link:

Amgen pays $2.7bn to harness BeiGene’s China marketing muscle

Amgen pays $2.7bn to harness BeiGene’s China marketing muscle

Pharmaforum

Flag link:

China could quickly become the world’s largest antidepressant market, but hurdles remain

China could quickly become the world’s largest antidepressant market, but hurdles remain

Marketwatch

antidepressants

Flag link:

Merck KGaA wants to get in early on Chinese innovation — so it's setting up a seed fund there

Merck KGaA wants to get in early on Chinese innovation — so it's setting up a seed fund there

Endpoints

Flag link:

With biosimilar threat under control (for now), Roche savors demand for its new drugs

With biosimilar threat under control (for now), Roche savors demand for its new drugs

Endpoints

Spark Therapeutics

Flag link:

Flow of US biotech VC dollars on track to match record 2018 levels — China? Not so much

Flow of US biotech VC dollars on track to match record 2018 levels — China? Not so much

Endpoints

venture capital

Flag link:

Merck’s KEYTRUDA approved as monotherapy in China for first-line treatment of certain patients with advanced NSCLC

Merck’s KEYTRUDA approved as monotherapy in China for first-line treatment of certain patients with advanced NSCLC

Pharmaceutical Business Review

non-small cell lung cancer

Flag link:

Pages